Back

Introduction - LDL-c: done deal, next epigenetics?

25 August 2018 (15:30 - 15:35)
Organised by:
Congress Presentation Part of: LDL-c: done deal, next epigenetics? (EBAC Accredited) Secondary Prevention ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Ulrich Laufs

University Hospital Leipzig, Leipzig (Germany)

4 More presentations in this session

Presentation thumbnail
The real residual risk in patients with cardiovascular disease and diabetes: the promise of epigenetics.
Professor E. Stroes (Amsterdam, NL)
Presentation thumbnail
Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.
Doctor J. Plutzky (Boston, US)
Presentation thumbnail
A clinical view on BET inhibition in targeting residual risk in cardiovascular disease and diabetes.
Professor K. Ray (London, GB)
Presentation thumbnail
Discussion and summary - LDL-c: done deal, next epigenetics? .
Professor U. Laufs (Leipzig, DE)

Access the full session

Session thumbnail
LDL-c: done deal, next epigenetics? (EBAC Accredited)

The Event

Event poster

ESC Congress 2018

25 August 2018 15:30 CET
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on role of epigenetics in cardiac health and disease.
27 August 2022
thumbnail
Webinar
How to treat patients with borderline dyslipidemia
8 February 2023
thumbnail
Congress Presentation
Integrated analysis of DNA methylation profile in HLA-G gene and imaging in coronary heart disease
28 August 2020
thumbnail
Congress Session
Genetics in heart failure
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources